MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results

Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05, Respectively Fourth Quarter Adjusted EBITDA¹ was $20 Million, or 21% of Net Sales Management to Host Conference Call Today, February 26, 2025, at 4:30 PM ET MARIETTA, Ga., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the fourth quarter and full year 2024. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "We are pleased today to report solid fourth quarter and full year 2024 results. With fourth quarter net sales growth of 7% year-over-year, an Adjusted EBITDA margin of 21% of net sales and yet another strong quarter of free cash flow, our business continued to drive impressive results to close out the year, even in the face of significant disruption caused by the ongoing manipulation of the Medicare reimbursement system in the private office." Mr. Capper continued, "I am as confident as ever in the enormous untapped clinical opportunities for our current and future products. We remain actively engaged with stakeholders at every level to adopt measures that will curb Medicare overpayments for skin substitutes and refocus our industry on evidence-based product innovation and patient outcomes." "As we head into 2025, we plan to grow our Wound and Surgical businesses by continuing to develop innovative products, generating compelling clinical evidence and strengthening our relationships with our customers. We are prepared to rapidly adjust to changes in the market as they unfold and remain confident MIMEDX has the ability to lead the market over both the short- and long-term," concluded Mr. Capper. Fourth Quarter and Full Year 2024 Results Discussion Net Sales MIMEDX reported net sales for the three months ended December 31, 2024 of $93 million, compared to $87 million for the three months ended December 31, 2023, an increase of 7%. For the full year 2024 MIMEDX reported net sales of $349 million, compared to $321 million in the prior year period, reflecting growth of 9%. In each case, the increase included contributions from newer products, which were partially offset by some of the lingering commercial challenges associated with sales team and customer turnover from earlier in the year. Gross Profit and Margin Gross profit for the three months ended December 31, 2024, was $76 million, an increase of $3 million as compared to the prior year period. Gross margin for the three months ended December 31, 2024 was 82%, compared to 84% in the prior year period. While fourth quarter 2024 gross margin was negatively impacted by the amortization of distribution rights stemming from acquisitions entered into during 2024, this impact was partially offset by favorable product mix and continued execution on improvements in manufacturing scale up, including reductions in scrap. On an adjusted basis, fourth quarter 2024 gross margin was 84%, which reflects a roughly flat adjusted gross margin compared to the prior year period. For the full year 2024, gross profit was $289 million, reflecting an increase of $22 million compared to the prior year period. Additionally, gross margin for the full year 2024 was 83%, compared to 83% for the full year 2023. On an adjusted basis, gross margin for the full year 2024 was 84% compared to 83% for the full year 2023. Operating Expenses Selling, general and administrative ("SG&A") expenses for the three months ended December 31, 2024, were $61 million compared to $54 million for the three months ended December 31, 2023. The increase in SG&A was driven by year-over-year increases in compensation related to higher salary and benefit costs from merit raises, promotions, as well as commissions driven by increases in sales and increases in effective commission rates. Incremental spend from legal and regulatory disputes in the current period also contributed to the increase. For the full year 2024, SG&A expenses totaled $225 million, compared to $211 million for the prior period, reflecting a year over year increase of 7%. Research and development ("R&D") expenses for the three months ended December 31, 2024, were $4 million compared to $2 million for the three months ended December 31, 2023. For the full year 2024, research and development expenses remained essentially flat at $12 million compared to 2023. R&D spend in the quarter and year was driven, in part, by the randomized controlled trial for EPIEFFECT and ongoing investments in the development of future products in our pipeline. Investigation, restatement and related expense for the three months ended December 31, 2024, was immaterial compared to $1 million of expense for the three months ended December 31, 2023. For the full year 2024, investigation, restatement and related expenses totaled a benefit of $9 million compared to expense of $5 million in 2023. The last material matter associated with our historical Audit Committee investigation concluded during 2024. We do not expect activity to be material in future periods. Net income from continuing operations for the three months and full year ended December 31, 2024 was $7 million and $42 million, respectively, compared to a net income from continuing operations of $51 million and $67 million for the three months and full year ended December 31, 2023, respectively. Net income from continuing operations in 2023 was significantly impacted by a $37 million reversal of a valuation allowance against our deferred tax assets. Cash and Cash Equivalents As of December 31, 2024, the Company had $104 million of cash and cash equivalents compared to $82 million as of December 31, 2023 and $89 million as of September 30, 2024. As of December 31, 2024, our cash position, net of debt on our balance sheet, was $86 million, representing a sequential increase of $16 million. Financial OutlookProvided that the future effective LCDs go into effect as currently planned, MIMEDX expects net sales growth of at least high single-digits as a percentage and Adjusted EBITDA margin above 20% for the full-year 2025. Longer-term, the Company continues to expect to achieve annual net sales growth in the low double-digits as a percentage with an Adjusted EBITDA margin above 20%. Conference Call and Webcast MIMEDX will host a conference call and webcast to review its fourth quarter and full year 2024 results on Wednesday, February 26, 2025, beginning at 4:30 p.m., Eastern Time. The call can be accessed using the following information: Webcast: Click here U.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13751444 A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event. Important Cautionary Statement This press release and our investor conference call include forward-looking statements, which reflect management's current beliefs and expectations regarding future events and operating performance and speak only as of the date hereof. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties. These statements include statements regarding: (i) future sales, sales growth, and Adjusted EBITDA margin; (ii) our longer term financial goals and expectations for future financial results, including levels of net sales, Adjusted EBITDA, and Adjusted EBITDA margin; (iii) our expectations regarding the size of the market for our products;(iv) our expectations regarding Medicare spending and timing of LCD implementation, if any; (v) continued growth in different care settings and different products; (vi) HELIOGEN to be a meaningful contributor to growth in 2025; (vii) our expected outcomes relating to improving workflow and strengthening bonds between the Company and its customers; and (viii) LCD implementation on the Company’s business. Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," “goal,” “outlook,” "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause actual results to differ from expectations include: (i) future sales are uncertain and are affected by competition, access to customers, patient access to healthcare providers, the reimbursement environment and many other factors; (ii) the Company may change its plans due to unforeseen circumstances; (iii) the results of scientific research are uncertain and may have little or no value; (iv) our ability to sell our products in other countries depends on a number of factors including adequate levels of reimbursement, market acceptance of novel therapies, and our ability to build and manage a direct sales force or third party distribution relationship; (v) the effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies; (vi) we may alter the timing and amount of planned expenditures for research and development based on regulatory developments; (vii) Medicare spending and delays in the implementation of the LCDs, if any; and (viii) changes in the size of the addressable market for our products. Additional factors that could impact outcomes and our results include those described in the Risk Factors section of our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the Company assumes no obligation to update any forward-looking statement. About MIMEDX MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com. Contact:Matt NotarianniInvestor Relations470.304.7291mnotarianni@mimedx.com Selected Unaudited Financial Information MiMedx Group, Inc.Condensed Consolidated Balance Sheets(in thousands) Unaudited December 31,2024 December 31,2023ASSETS Current assets: Cash and cash equivalents $104,416 $82,000 Accounts receivable, net 55,828 53,871 Inventory 23,807 21,021 Prepaid expenses 5,018 5,624 Other current assets 2,817 1,745 Total current assets 191,886 164,261 Property and equipment, net 5,944 6,974 Right of use asset 5,606 2,132 Deferred tax asset, net 28,306 40,777 Goodwill 19,441 19,441 Intangible assets, net 11,626 5,257 Other assets 1,106 205 Total assets $263,915 $239,047 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Current portion of long term debt $1,000 $1,000 Accounts payable 7,409 9,048 Accrued compensation 23,667 22,353 Accrued expenses 9,012 9,361 Current portion of Profit Share Payments 1,421 — Current liabilities of discontinued operations — 1,352 Other current liabilities 3,086 2,894 Total current liabilities 45,595 46,008 Long term debt, net 17,830 48,099 Other liabilities 7,383 2,223 Total liabilities $70,808 $96,330 Total stockholders' equity 193,107 142,717 Total liabilities and stockholders’ equity $263,915 $239,047 MiMedx Group, Inc.Condensed Consolidated Statements of Operations(in thousands, except share and per share amounts) Unaudited Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 Net sales $92,907 $86,832 $348,879 $321,477 Cost of sales 16,909 13,841 60,073 54,634 Gross profit 75,998 72,991 288,806 266,843 Operating expenses: Selling, general and administrative 61,043 54,352 225,087 211,124 Research and development 3,571 2,434 12,341 12,665 Investigation, restatement and related 43 524 (8,698) 5,176 Amortization of intangible assets 194 192 765 762 Impairment of intangible assets 94 — 446 — Operating income 11,053 15,489 58,865 37,116 Other expense, net Interest income (expense), net 403 (1,593) (1,006) (6,457)Other (expense) income, net (208) 16 (565) (26)Income from continuing operations before income tax provision 11,248 13,912 57,294 30,633 Income tax provision (3,811) 37,375 (15,296) 36,806 Net income from continuing operations 7,437 51,287 41,998 67,439 Income (loss) from discontinued operations, net of tax — 2,189 421 (9,211)Net income $7,437 $53,476 $42,419 $58,228 Net income available to common stockholders from continuing operations $7,437 $44,829 $41,998 $55,796 Basic net income per common share: Continuing operations $0.05 $0.38 $0.29 $0.48 Discontinued operations $— $0.02 $— $(0.08)Basic net income per common share $0.05 $0.40 $0.29 $0.40 Diluted net income per common share: Continuing operations $0.05 $0.31 0.28 0.43 Discontinued operations — 0.01 — (0.06)Diluted net income per common share $0.05 $0.32 $0.28 $0.37 Weighted average common shares outstanding - basic 147,008,235 119,367,482 146,979,354 116,495,810 Weighted average common shares outstanding - diluted 149,242,415 148,076,079 149,049,197 145,962,462 MiMedx Group, Inc.Condensed Consolidated Statements of Cash Flows(in thousands) Unaudited Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 Net cash flows provided by operating activities $18,782 $10,257 $66,198 $26,775 Net cash flows used in investing activities (2,767) (481) (9,583) (2,155)Net cash flows used in financing activities (400) (8,940) (34,199) (8,570)Net change in cash $15,615 $836 $22,416 $16,050 Reconciliation of Non-GAAP Measures In addition to our GAAP results, we provide certain non-GAAP measures including Adjusted EBITDA, related margins, Free Cash Flow, Adjusted Gross Profit, Adjusted Gross Margin and Adjusted Net Income. We believe that the presentation of these measures provides important supplemental information to management and investors regarding our performance. These measures are not a substitute for GAAP measures. Company management uses these non-GAAP measures as aids in monitoring our ongoing financial performance from quarter-to-quarter and year-to-year on a regular basis and for benchmarking against comparable companies. These non-GAAP financial measures reflect the exclusion of the following items: Share-based compensation expense – expense recognized related to awards to employees and our board of directors pursuant to our share-based compensation plans. This expense is reflected amongst cost of sales, research and development expense, and selling, general, and administrative expense in the unaudited condensed consolidated statements of operations.Investigation, restatement, and related (benefit) expense – expenses incurred toward the legal defense of the Company and advanced on behalf of certain former officers and directors, net of negotiated reductions and settlements of amounts previously advanced, related to certain legal matters. This expense is reflected in the line of the same name in our unaudited condensed consolidated statements of operations.Impairment of intangible assets – reflects the impairment of intangibles. This expense is reflected in the line of the same name in our unaudited condensed consolidated statements of operations.Transaction-related expenses – reflects expenses incrementally incurred resulting from the consummation of material strategic transactions or the integration of acquired assets or operations into our core business. With respect to the three months and year ended December 31, 2024, this relates to our acquisition and integration of exclusive distribution rights to HELIOGEN.Strategic legal and regulatory expenses – With respect to the three months and year ended December 31, 2024, this relates to litigation and regulatory expenses. Litigation expenses incurred relate to suits filed against former employees and their employers for violation of non-compete and non-solicitation agreements and related matters. Regulatory expenses relate to legal fees incurred stemming from action taken against the United States Food & Drug Administration ("FDA") surrounding the designation of one of our products.Loss on extinguishment of debt – reflects the excess of cash paid to extinguish debt over the carrying value of the debt on our balance sheet upon the repayment and termination of a loan agreement. With respect to the year ended December 31, 2024, this relates to the repayment and termination of the Company's loan agreement with Hayfin. Amounts in this line reflect (i) prepayment premium paid and (ii) write-offs of unamortized original issue discount and deferred financing costs.Expenses related to the Disbanding of Regenerative Medicine – incremental expenses recognized or incurred directly as a result of our announcement to disband our Regenerative Medicine segment.Amortization of acquired intangible assets – reflects amortization expense recognized solely related to assets which were acquired as part of a transaction. With respect to the three months and year ended December 31, 2024, this relates solely to the amortization of distribution rights stemming from the TELA Bio, Inc. and Regenity Biosciences agreements entered into during the first quarter of 2024. These expenses are reflected in cost of sales in our consolidated statements of operations.Reorganization expenses – reflects severance expense incurred arising from separations from certain officers of the Company.Income Tax Adjustment – for purposes of calculating Adjusted Net Income and Adjusted Earnings Per Share, reflects our expectation of a long-term effective tax rate, which is normalized and balance sheet-agnostic. Actual reporting tax expense will be based on GAAP earnings, and may differ from the expected long-term effective tax rate due to a variety of factors, including the tax treatment of various transactions included in GAAP net income and other reconciling items that are excluded in determining Adjusted Net Income and Adjusted EPS. The actual long-term normalized effective tax rate was 25% for each of the years ended December 31, 2024 and 2023. Adjusted EBITDA and Adjusted EBITDA margin Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation, (ii) amortization of intangibles, (iii) interest (income) expense, net, (iv) income tax provision, (v) share-based compensation, (vi) investigation, restatement and related expenses, (vii) expenses related to disbanding of the Regenerative Medicine business unit, (viii) strategic legal and regulatory expenses, (ix) transaction-related expenses, (x) impairment of intangible assets, and (xi) reorganization expenses. Please refer to the tables at the beginning of this press release for reconciliation to GAAP net income (loss). Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 Net Income $7,437 $53,476 $42,419 $58,228 Non-GAAP Adjustments: Depreciation expense 564 611 2,279 2,665 Amortization of intangible assets 2,426 192 3,762 762 Interest (income) expense, net (403) 1,593 1,006 6,457 Income tax provision 3,811 (40,349) 15,296 (39,780)Share-based compensation 4,693 4,385 16,933 17,178 Investigation, restatement and related expenses 44 524 (8,698) 5,176 Impairment of intangible assets 94 — 446 — Transaction related expenses (38) — 612 — Strategic legal and regulatory expenses 1,140 — 2,806 — Expenses related to disbanding of Regenerative Medicine Business Unit — 785 (421) 6,384 Reorganization expenses — — — 1,412 Adjusted EBITDA $19,768 $21,217 $76,440 $58,482 Adjusted EBITDA margin 21.3% 24.4% 21.9% 18.2% Adjusted Net Income and Adjusted Gross Margin Adjusted Net Income provides a view of our operating performance, exclusive of certain items which are non-recurring or not reflective of our core operations. Adjusted Net Income is defined as GAAP net income plus (i) loss on extinguishment of debt, (ii) investigation restatement and related expenses, (iii) impairment of intangible assets, (iv) amortization of acquired intangible assets, (v) transaction related expenses, (vi) strategic legal and regulatory expenses, and (vii) expenses related to disbanding of our Regenerative Medicine business unit, and (viii) the long-term effective income tax rate adjustment. Each of the adjustments to reconcile Adjusted Net Income to GAAP net income affect individual financial statement captions which are reflected in our consolidated statements of operations, including gross profit. Adjusted Gross Profit is therefore defined as GAAP gross profit plus (i) loss on extinguishment of debt, (ii) investigation restatement and related expenses, (iii) impairment of intangible assets, (iv) amortization of acquired intangible assets, (v) transaction related expenses, (vi) strategic legal and regulatory expenses, and (vii) expenses related to disbanding of our Regenerative Medicine business unit, and (viii) the long-term effective income tax rate adjustment., to the extent that these adjustments impact GAAP gross profit. Adjusted Gross Margin is calculated as Adjusted Gross Profit divided by GAAP net sales. A reconciliation of GAAP net income to Adjusted Net Income appears in the table below (in thousands): Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 Net income $7,437 $53,476 $42,419 $58,228 Loss on extinguishment of debt — — 1,401 — Investigation, restatement and related expenses 43 524 (8,698) 5,176 Impairment of intangible assets 94 — 446 — Amortization of acquired intangible assets 2,232 — 2,997 — Transaction-related expenses (38) — 612 — Strategic legal and regulatory expenses 1,140 — 2,806 — Expenses related to disbanding of Regenerative Medicine Business Unit — 785 (421) 6,384 Reorganization expenses — — — 1,412 Long-term effective income tax rate adjustment 130 (43,958) 1,082 (47,635)Adjusted net income $11,038 $10,827 $42,644 $23,565 A reconciliation of various line items included in our GAAP unaudited condensed consolidated statements of operations to Adjusted Net Income, including Adjusted Gross Profit for the three months and year ended December 31, 2024 and 2023 are presented in the tables below (in thousands): Three Months Ended December 31, 2024 Gross Profit Selling, General & Administrative Expense Research and Development Expense Net IncomeReported GAAP Measure $75,998 $61,043 $3,571 $7,437 Investigation, restatement and related expenses — — — 43 Impairment of intangible assets — — — 94 Amortization of acquired intangible assets 2,232 — — 2,232 Transaction-related expenses — (30) — (38)Strategic legal and regulatory expenses — (1,140) — 1,140 Expenses related to disbanding of Regenerative Medicine Business Unit — — — — Long-term effective income tax rate adjustment — — — 130 Non-GAAP Measure $78,230 $59,873 $3,571 $11,038 Gross Profit Margin 81.8% Adjusted Gross Profit Margin 84.2% Three months ended December 31, 2023 Gross Profit Selling, General & Administrative Expense Research and Development Expense Net IncomeReported GAAP Measure $72,991 $54,352 $2,434 $53,476 Investigation, restatement and related expenses — — — 524 Amortization of acquired intangibles — — — — Expenses related to disbanding of Regenerative Medicine Business Unit — — — 785 Long-term effective income tax rate adjustment — — — (43,958)Non-GAAP Measure $72,991 $54,352 $2,434 $10,827 Gross Profit Margin 84.1% Adjusted Gross Profit Margin 84.1% Year Ended December 31, 2024 Gross Profit Selling, General & Administrative Expense Research and Development Expense Net IncomeReported GAAP Measure $288,806 $225,087 $12,341 $42,419 Loss on extinguishment of debt — — — 1,401 Investigation, restatement and related expenses — — — (8,698)Impairment of intangible assets — — — 446 Amortization of acquired intangible assets 2,997 — — 2,997 Transaction-related expenses — (551) — 612 Strategic legal and regulatory expenses — (2,806) — 2,806 Expenses related to disbanding of Regenerative Medicine Business Unit — — — (421)Long-term effective income tax rate adjustment — — — 1,082 Non-GAAP Measure $291,803 $221,730 $12,341 $42,644 Gross Profit Margin 82.8% Adjusted Gross Profit Margin 83.6% Year Ended December 31, 2023 Gross Profit Selling, General & Administrative Expense Research and Development Expense Net IncomeReported GAAP Measure $266,843 $211,124 $12,665 58,228 Investigation, restatement and related expenses — — — 5,176 Amortization of acquired intangible assets — — — — Expenses related to disbanding of Regenerative Medicine Business Unit — — — 6,384 Reorganization expenses — (1,412) — 1,412 Long-term effective income tax rate adjustment — — — (47,635)Non-GAAP Measure $266,843 $209,712 $12,665 $23,565 Gross Profit Margin 83.0% Adjusted Gross Profit Margin 83.0% Adjusted Earnings Per Share Adjusted Earnings Per Share is intended to provide a normalized view of earnings per share by removing items that may be irregular, one-time, or non-recurring from net income. This enables us to identify underlying trends in our business that could otherwise be masked by such items. Adjusted Earnings Per Share consists of GAAP diluted net income (loss) per common share including adjustments for: (i) loss on extinguishment of debt, (ii) investigation restatement and related expenses, (iii) impairment of intangible assets, (iv) amortization of acquired intangible assets, (v) transaction related expenses, (vi) strategic legal and regulatory expenses, (vii) expenses related to disbanding of our Regenerative Medicine business unit, (viii) reorganization expenses, (ix) the long-term effective income tax rate adjustment, and (x) the effect of antidilution. The effect of antidilution reflects the changes resulting from the removal of the dilutive impact of convertible securities which were dilutive for purposes of calculating GAAP net income per common share, but are antidilutive for non-GAAP purposes. A reconciliation of GAAP diluted earnings per share to Adjusted Earnings Per Share appears in the table below (per diluted share): Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 GAAP net income per common share - diluted $0.05 $0.32 $0.28 $0.37 Loss on extinguishment of debt 0.00 0.00 0.01 0.00 Investigation, restatement and related (benefit) expense 0.00 0.00 (0.06) 0.04 Impairment of intangible assets 0.00 0.00 0.00 0.00 Amortization of acquired intangible assets 0.01 0.00 0.02 0.00 Transaction-related expenses 0.00 0.00 0.00 0.00 Strategic legal and regulatory expenses 0.01 0.00 0.02 0.00 Expenses related to disbanding of Regenerative Medicine business unit 0.00 0.01 0.00 0.05 Reorganization expenses 0.00 0.00 0.00 0.01 Long-term effective income tax rate adjustment 0.00 (0.36) 0.01 (0.40)Effects of antidilution 0.00 0.07 0.00 0.03 Adjusted Earnings Per Share $0.07 $0.04 $0.29 $0.10 Weighted average common shares outstanding - adjusted 149,242,415 122,740,917 149,049,197 118,504,557 Free Cash Flow Free Cash Flow is intended to provide a measure of our ability to generate cash in excess of capital investments. It provides management with a view of cash flows which can be used to finance operational and strategic investments. Free Cash Flow is defined as net cash provided by operating activities less capital expenditures, including purchases of equipment. A reconciliation of GAAP net cash flows provided by operating activities to Free Cash Flow appears in the table below (in thousands): Three Months Ended December 31, Year Ended December 31, 2024 2023 2024 2023 Net cash flows provided by operating activities $18,782 $10,257 66,198 26,775 Capital expenditures, including purchases of equipment (263) (427) (1,683) (1,987)Free Cash Flow $18,519 $9,830 $64,515 $24,788 Other Information Net Sales by Product Category by Quarter Below is a summary of net sales by product category (in thousands): 2024 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4Wound $57,049 $57,547 $55,052 $61,357 $45,206 $53,318 $51,156 $55,980 Surgical 27,660 29,660 29,005 31,550 26,470 27,939 30,556 30,852 Net sales $84,709 $87,207 $84,057 $92,907 $71,676 $81,257 $81,712 $86,832 Selling, General and Administrative Below is the breakout of selling, general and administrative expense by selling and marketing and general and administrative (in thousands): 2024 2023 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4Selling and marketing $44,477 $41,725 $41,721 $47,638 $39,158 $40,239 $40,441 $42,000 General and administrative 10,652 13,676 11,795 13,403 13,092 11,716 12,130 12,348 Selling, general and administrative $55,129 $55,401 $53,516 $61,041 $52,250 $51,955 $52,571 $54,348 ________________________________¹ Adjusted EBITDA is a Non-GAAP Measure. This press release contains this and other Non-GAAP measures. For reconciliations of our Non-GAAP measures to their nearest GAAP measure, refer to the section titled "Reconciliation of Non-GAAP Measures" below.

MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results

FAQ

Why Bullish?

How important is it?

Why Long Term?

Related Companies

Related News